BUSINESS

• Lilly’s Japan Sales Slip 2% to US$1.9 Billion in 2015
  February 12, 2016

• Sakigake: Now and Future (2) - Shionogi Aims to Submit Application for Novel Flu Drug as Early as FY2017
  February 12, 2016

• New CSL Japan Chief Eager to See Annual Sales of 40 Billion Yen in 5 Years
  February 10, 2016

• Asahi Kasei President to Step Down over Piling Data Scandal
  February 10, 2016

• Daiichi Sankyo to Close UK Development Unit
  February 10, 2016

• Otsuka Licenses US Rights for PDE4 Inhibitor to Medimetriks
  February 10, 2016

• Ethical Drug Sales Up 5.7% in December: Crecon Report
  February 10, 2016

• Gilead, Bristol Take Quantum Leaps in 2015, Lilly Logs Double-Digit Growth: IMS
  February 10, 2016

• Japan Sales of “Huge Seller” Quartet Each Break 110 Billion Yen in 2015: IMS
  February 10, 2016

• Mundipharma Gearing Up for Full-Blown Oncology Business in Japan
  February 9, 2016

• AZ Posts Japan Sales of US$2 Billion in 2015, Down 9% in Actual Terms
  February 9, 2016

• Anticancer Peptide-Drug Conjugates Could Overcome Problems with ADCs: PeptiDream
  February 9, 2016

• PeptiDream Joins Hands with Shionogi, 5th Japanese Partner
  February 8, 2016

• Takeda Expands ADC Collaboration with US Startup Mersana
  February 5, 2016

• FDA Panel Backs Effectiveness of Brintellix for Cognitive Dysfunction
  February 5, 2016

• Mitsubishi Tanabe to Establish Stand-Alone Sales Structure via New US Subsidiary
  February 5, 2016

• BMS, Pfizer to Codevelop Factor Xa Antidote in Japan
  February 5, 2016

• Ayumi Poised to In-License Several RA Biosimilars, Eyes 50 Billion Yen Sales by 2020
  February 5, 2016

• Takeda to Spin Off Consumer Healthcare Unit, New Firm to Go Live in April 2017
  February 4, 2016

• Kyorin Ends Development of COPD Combo Drug, Returns Rights to AZ
  February 4, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 482
• 483
• 484
• 485
• 486
• 487
• 488
• 489
• 490
• …
• Next ›
• 最終 »